25 XP   0   0   10

Tianjin Lisheng Pharmaceutical Co Ltd
Buy, Hold or Sell?

Let's analyse Tianjin Lisheng Pharmaceutical Co Ltd together

PenkeI guess you are interested in Tianjin Lisheng Pharmaceutical Co Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Tianjin Lisheng Pharmaceutical Co Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Tianjin Lisheng Pharmaceutical Co Ltd

I send you an email if I find something interesting about Tianjin Lisheng Pharmaceutical Co Ltd.

Quick analysis of Tianjin Lisheng Pharmaceutical Co Ltd (30 sec.)










What can you expect buying and holding a share of Tianjin Lisheng Pharmaceutical Co Ltd? (30 sec.)

How much money do you get?

How much money do you get?
¥0.08
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
¥26.61
Expected worth in 1 year
¥29.61
How sure are you?
92.5%

+ What do you gain per year?

Total Gains per Share
¥3.61
Return On Investment
14.6%

For what price can you sell your share?

Current Price per Share
¥24.76
Expected price per share
¥17.66 - ¥26.18
How sure are you?
50%

1. Valuation of Tianjin Lisheng Pharmaceutical Co Ltd (5 min.)




Live pricePrice per Share (EOD)

¥24.76

Intrinsic Value Per Share

¥50.08 - ¥59.91

Total Value Per Share

¥76.69 - ¥86.52

2. Growth of Tianjin Lisheng Pharmaceutical Co Ltd (5 min.)




Is Tianjin Lisheng Pharmaceutical Co Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$676.6m$610.7m$22.2m3.5%

How much money is Tianjin Lisheng Pharmaceutical Co Ltd making?

Current yearPrevious yearGrowGrow %
Making money$12.4m$3.2m$9.2m74.1%
Net Profit Margin33.7%7.5%--

How much money comes from the company's main activities?

3. Financial Health of Tianjin Lisheng Pharmaceutical Co Ltd (5 min.)




What can you expect buying and holding a share of Tianjin Lisheng Pharmaceutical Co Ltd? (5 min.)

Welcome investor! Tianjin Lisheng Pharmaceutical Co Ltd's management wants to use your money to grow the business. In return you get a share of Tianjin Lisheng Pharmaceutical Co Ltd.

What can you expect buying and holding a share of Tianjin Lisheng Pharmaceutical Co Ltd?

First you should know what it really means to hold a share of Tianjin Lisheng Pharmaceutical Co Ltd. And how you can make/lose money.

Speculation

The Price per Share of Tianjin Lisheng Pharmaceutical Co Ltd is ¥24.76. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Tianjin Lisheng Pharmaceutical Co Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Tianjin Lisheng Pharmaceutical Co Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ¥26.61. Based on the TTM, the Book Value Change Per Share is ¥0.75 per quarter. Based on the YOY, the Book Value Change Per Share is ¥-0.08 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ¥0.15 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Tianjin Lisheng Pharmaceutical Co Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share
Usd Eps0.010.1%0.070.3%0.030.1%0.030.1%0.030.1%
Usd Book Value Change Per Share0.190.8%0.100.4%-0.010.0%0.060.3%0.040.1%
Usd Dividend Per Share0.000.0%0.020.1%0.020.1%0.010.1%0.030.1%
Usd Total Gains Per Share0.200.8%0.120.5%0.010.0%0.080.3%0.060.3%
Usd Price Per Share3.60-3.39-3.04-3.20-3.97-
Price to Earnings Ratio62.75-28.91-25.86-28.37-41.27-
Price-to-Total Gains Ratio18.40-54.46-190.92-105.22-112.12-
Price to Book Ratio0.98-0.99-0.92-0.95-1.53-
Price-to-Total Gains Ratio18.40-54.46-190.92-105.22-112.12-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.41688
Number of shares292
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.020.01
Usd Book Value Change Per Share0.100.06
Usd Total Gains Per Share0.120.08
Gains per Quarter (292 shares)36.4022.71
Gains per Year (292 shares)145.5990.82
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
125121136177481
24924228234148172
37436342851222263
49848457468296354
512360572084370445
6148726866101444536
71728471012118518627
81979681158135591718
922110891304152665809
1024612101450169739900

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%19.01.00.095.0%37.01.02.092.5%53.01.02.094.6%
Book Value Change Per Share3.01.00.075.0%9.03.00.075.0%13.07.00.065.0%27.013.00.067.5%39.017.00.069.6%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%40.00.00.0100.0%53.00.03.094.6%
Total Gains per Share4.00.00.0100.0%11.01.00.091.7%17.03.00.085.0%37.03.00.092.5%51.05.00.091.1%

Fundamentals of Tianjin Lisheng Pharmaceutical Co Ltd

About Tianjin Lisheng Pharmaceutical Co Ltd

Tianjin Lisheng Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. It offers its products in various forms comprising tablets, soft and hard capsules, granules, dripping pills, freeze-dried powder injections, and water injections for use in various therapeutic fields, such as circulatory system, systemic anti-infection, digestive system, nervous and endocrine system, respiratory system, musculoskeletal, and genitourinary system, as well as antitumor and immune system modulation, and big health series products. The company also provides Chinese and Western medicines; biological preparations, oral liquids, and raw materials; and intermediates, diagnostic reagents, biochemical reagents, plastic bottles, and raw materials. It also exports its products. The company was founded in 1951 and is based in Tianjin, China. Tianjin Lisheng Pharmaceutical Co.,Ltd. operates as a subsidiary of Tianjin Pharmaceutical Holdings Co., Ltd.

Fundamental data was last updated by Penke on 2024-04-14 15:50:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is fair priced.

1.1. Profitability of Tianjin Lisheng Pharmaceutical Co Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Tianjin Lisheng Pharmaceutical Co Ltd earns for each ¥1 of revenue.

  • Above 10% is considered healthy but always compare Tianjin Lisheng Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 7.9% means that ¥0.08 for each ¥1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Tianjin Lisheng Pharmaceutical Co Ltd:

  • The MRQ is 7.9%. The company is making a profit. +1
  • The TTM is 33.7%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ7.9%TTM33.7%-25.7%
TTM33.7%YOY7.5%+26.2%
TTM33.7%5Y12.5%+21.1%
5Y12.5%10Y12.5%+0.1%
1.1.2. Return on Assets

Shows how efficient Tianjin Lisheng Pharmaceutical Co Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Tianjin Lisheng Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.3% Return on Assets means that Tianjin Lisheng Pharmaceutical Co Ltd generated ¥0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Tianjin Lisheng Pharmaceutical Co Ltd:

  • The MRQ is 0.3%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 1.6%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ0.3%TTM1.6%-1.3%
TTM1.6%YOY0.4%+1.2%
TTM1.6%5Y0.7%+0.9%
5Y0.7%10Y0.8%-0.1%
1.1.3. Return on Equity

Shows how efficient Tianjin Lisheng Pharmaceutical Co Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Tianjin Lisheng Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.4% Return on Equity means Tianjin Lisheng Pharmaceutical Co Ltd generated ¥0.00 for each ¥1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Tianjin Lisheng Pharmaceutical Co Ltd:

  • The MRQ is 0.4%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 2.0%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.4%TTM2.0%-1.6%
TTM2.0%YOY0.5%+1.4%
TTM2.0%5Y0.9%+1.1%
5Y0.9%10Y1.0%-0.1%

1.2. Operating Efficiency of Tianjin Lisheng Pharmaceutical Co Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Tianjin Lisheng Pharmaceutical Co Ltd is operating .

  • Measures how much profit Tianjin Lisheng Pharmaceutical Co Ltd makes for each ¥1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Tianjin Lisheng Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ¥0.00  for each ¥1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Tianjin Lisheng Pharmaceutical Co Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM9.7%-9.7%
TTM9.7%YOY6.0%+3.7%
TTM9.7%5Y7.1%+2.6%
5Y7.1%10Y4.4%+2.7%
1.2.2. Operating Ratio

Measures how efficient Tianjin Lisheng Pharmaceutical Co Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.41 means that the operating costs are ¥1.41 for each ¥1 in net sales.

Let's take a look of the Operating Ratio trends of Tianjin Lisheng Pharmaceutical Co Ltd:

  • The MRQ is 1.410. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.297. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.410TTM1.297+0.113
TTM1.297YOY1.357-0.059
TTM1.2975Y1.306-0.009
5Y1.30610Y0.904+0.402

1.3. Liquidity of Tianjin Lisheng Pharmaceutical Co Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Tianjin Lisheng Pharmaceutical Co Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 4.50 means the company has ¥4.50 in assets for each ¥1 in short-term debts.

Let's take a look of the Current Ratio trends of Tianjin Lisheng Pharmaceutical Co Ltd:

  • The MRQ is 4.501. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.073. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.501TTM4.073+0.428
TTM4.073YOY3.415+0.658
TTM4.0735Y3.926+0.147
5Y3.92610Y2.205+1.721
1.3.2. Quick Ratio

Measures if Tianjin Lisheng Pharmaceutical Co Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Tianjin Lisheng Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.33 means the company can pay off ¥0.33 for each ¥1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Tianjin Lisheng Pharmaceutical Co Ltd:

  • The MRQ is 0.328. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.571. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.328TTM0.571-0.243
TTM0.571YOY0.625-0.054
TTM0.5715Y0.641-0.070
5Y0.64110Y0.900-0.260

1.4. Solvency of Tianjin Lisheng Pharmaceutical Co Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Tianjin Lisheng Pharmaceutical Co Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Tianjin Lisheng Pharmaceutical Co Ltd to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.15 means that Tianjin Lisheng Pharmaceutical Co Ltd assets are financed with 15.2% credit (debt) and the remaining percentage (100% - 15.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Tianjin Lisheng Pharmaceutical Co Ltd:

  • The MRQ is 0.152. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.166. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.152TTM0.166-0.014
TTM0.166YOY0.170-0.004
TTM0.1665Y0.160+0.006
5Y0.16010Y0.145+0.015
1.4.2. Debt to Equity Ratio

Measures if Tianjin Lisheng Pharmaceutical Co Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Tianjin Lisheng Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 17.9% means that company has ¥0.18 debt for each ¥1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Tianjin Lisheng Pharmaceutical Co Ltd:

  • The MRQ is 0.179. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.199. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.179TTM0.199-0.020
TTM0.199YOY0.205-0.006
TTM0.1995Y0.191+0.008
5Y0.19110Y0.171+0.020

2. Market Valuation of Tianjin Lisheng Pharmaceutical Co Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ¥1 in earnings Tianjin Lisheng Pharmaceutical Co Ltd generates.

  • Above 15 is considered overpriced but always compare Tianjin Lisheng Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 62.75 means the investor is paying ¥62.75 for every ¥1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Tianjin Lisheng Pharmaceutical Co Ltd:

  • The EOD is 59.529. Based on the earnings, the company is expensive. -2
  • The MRQ is 62.750. Based on the earnings, the company is expensive. -2
  • The TTM is 28.909. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD59.529MRQ62.750-3.222
MRQ62.750TTM28.909+33.842
TTM28.909YOY25.863+3.046
TTM28.9095Y28.368+0.540
5Y28.36810Y41.269-12.901
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Tianjin Lisheng Pharmaceutical Co Ltd:

  • The EOD is 10.929. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 11.521. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 34.912. Based on how much money comes from the company's main activities, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD10.929MRQ11.521-0.591
MRQ11.521TTM34.912-23.392
TTM34.912YOY23.183+11.729
TTM34.9125Y-247.128+282.040
5Y-247.12810Y-123.564-123.564
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Tianjin Lisheng Pharmaceutical Co Ltd is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Tianjin Lisheng Pharmaceutical Co Ltd:

  • The EOD is 0.931. Based on the equity, the company is cheap. +2
  • The MRQ is 0.981. Based on the equity, the company is cheap. +2
  • The TTM is 0.986. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.931MRQ0.981-0.050
MRQ0.981TTM0.986-0.006
TTM0.986YOY0.917+0.069
TTM0.9865Y0.952+0.034
5Y0.95210Y1.531-0.578
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Tianjin Lisheng Pharmaceutical Co Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1.4130.751+88%-0.083+106%0.459+208%0.268+426%
Book Value Per Share--26.60924.896+7%24.023+11%24.284+10%20.334+31%
Current Ratio--4.5014.073+10%3.415+32%3.926+15%2.205+104%
Debt To Asset Ratio--0.1520.166-9%0.170-11%0.160-5%0.145+5%
Debt To Equity Ratio--0.1790.199-10%0.205-13%0.191-6%0.171+5%
Dividend Per Share--0.0060.153-96%0.150-96%0.105-95%0.183-97%
Eps--0.1040.491-79%0.216-52%0.228-54%0.201-48%
Free Cash Flow Per Share--0.5660.188+202%0.394+44%0.174+226%0.174+226%
Free Cash Flow To Equity Per Share--0.5660.036+1456%0.244+132%0.061+833%0.061+833%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.950+5%
Intrinsic Value_10Y_max--59.913--------
Intrinsic Value_10Y_min--50.079--------
Intrinsic Value_1Y_max--1.702--------
Intrinsic Value_1Y_min--1.669--------
Intrinsic Value_3Y_max--8.392--------
Intrinsic Value_3Y_min--7.946--------
Intrinsic Value_5Y_max--19.035--------
Intrinsic Value_5Y_min--17.386--------
Market Cap4561906001.920-5%4809629491.2004524344578.560+6%4059377786.240+18%4267063652.224+13%5305032995.904-9%
Net Profit Margin--0.0790.337-76%0.075+7%0.125-37%0.125-36%
Operating Margin---0.097-100%0.060-100%0.071-100%0.044-100%
Operating Ratio--1.4101.297+9%1.357+4%1.306+8%0.904+56%
Pb Ratio0.931-5%0.9810.986-1%0.917+7%0.952+3%1.531-36%
Pe Ratio59.529-5%62.75028.909+117%25.863+143%28.368+121%41.269+52%
Price Per Share24.760-5%26.10024.555+6%22.033+18%23.160+13%28.793-9%
Price To Free Cash Flow Ratio10.929-5%11.52134.912-67%23.183-50%-247.128+2245%-123.564+1173%
Price To Total Gains Ratio17.456-5%18.40154.458-66%190.916-90%105.216-83%112.123-84%
Quick Ratio--0.3280.571-43%0.625-48%0.641-49%0.900-64%
Return On Assets--0.0030.016-80%0.004-24%0.007-53%0.008-59%
Return On Equity--0.0040.020-80%0.005-25%0.009-54%0.010-59%
Total Gains Per Share--1.4180.903+57%0.067+2015%0.563+152%0.451+214%
Usd Book Value--676673318.702633038061.736+7%610799394.171+11%617446521.962+10%517002278.819+31%
Usd Book Value Change Per Share--0.1950.104+88%-0.011+106%0.063+208%0.037+426%
Usd Book Value Per Share--3.6723.436+7%3.315+11%3.351+10%2.806+31%
Usd Dividend Per Share--0.0010.021-96%0.021-96%0.014-95%0.025-97%
Usd Eps--0.0140.068-79%0.030-52%0.031-54%0.028-48%
Usd Free Cash Flow--14403013.0804770921.125+202%10021124.756+44%3536656.392+307%1768328.196+714%
Usd Free Cash Flow Per Share--0.0780.026+202%0.054+44%0.024+226%0.024+226%
Usd Free Cash Flow To Equity Per Share--0.0780.005+1456%0.034+132%0.008+833%0.008+833%
Usd Market Cap629543028.265-5%663728869.786624359551.841+6%560194134.501+18%588854784.007+13%732094553.435-9%
Usd Price Per Share3.417-5%3.6023.389+6%3.040+18%3.196+13%3.973-9%
Usd Profit--2644324.79012483065.656-79%3229429.062-18%5342619.185-51%4895082.613-46%
Usd Revenue--33321525.81039779631.661-16%39557333.768-16%42418969.548-21%38213099.719-13%
Usd Total Gains Per Share--0.1960.125+57%0.009+2015%0.078+152%0.062+214%
 EOD+4 -4MRQTTM+20 -15YOY+20 -155Y+18 -1710Y+16 -20

3.2. Fundamental Score

Let's check the fundamental score of Tianjin Lisheng Pharmaceutical Co Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1559.529
Price to Book Ratio (EOD)Between0-10.931
Net Profit Margin (MRQ)Greater than00.079
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.328
Current Ratio (MRQ)Greater than14.501
Debt to Asset Ratio (MRQ)Less than10.152
Debt to Equity Ratio (MRQ)Less than10.179
Return on Equity (MRQ)Greater than0.150.004
Return on Assets (MRQ)Greater than0.050.003
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Tianjin Lisheng Pharmaceutical Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose24.700
Total0/1 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in CNY. All numbers in thousands.

Summary
Total Assets5,780,604
Total Liabilities877,174
Total Stockholder Equity4,903,430
 As reported
Total Liabilities 877,174
Total Stockholder Equity+ 4,903,430
Total Assets = 5,780,604

Assets

Total Assets5,780,604
Total Current Assets2,818,535
Long-term Assets2,962,069
Total Current Assets
Cash And Cash Equivalents 1,988,965
Short-term Investments 160,544
Net Receivables 44,728
Inventory 176,284
Other Current Assets 75,344
Total Current Assets  (as reported)2,818,535
Total Current Assets  (calculated)2,445,866
+/- 372,669
Long-term Assets
Property Plant Equipment 976,559
Intangible Assets 124,858
Long-term Assets Other 184,711
Long-term Assets  (as reported)2,962,069
Long-term Assets  (calculated)1,286,129
+/- 1,675,940

Liabilities & Shareholders' Equity

Total Current Liabilities626,267
Long-term Liabilities250,907
Total Stockholder Equity4,903,430
Total Current Liabilities
Short Long Term Debt 28,605
Accounts payable 90,363
Other Current Liabilities 1,662
Total Current Liabilities  (as reported)626,267
Total Current Liabilities  (calculated)120,630
+/- 505,637
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt3,948
Long-term Liabilities Other 3,580
Long-term Liabilities  (as reported)250,907
Long-term Liabilities  (calculated)7,527
+/- 243,380
Total Stockholder Equity
Retained Earnings 1,393,729
Total Stockholder Equity (as reported)4,903,430
Total Stockholder Equity (calculated)1,393,729
+/- 3,509,700
Other
Capital Stock184,277
Common Stock Shares Outstanding 184,277
Net Invested Capital 4,932,035
Net Working Capital 2,192,268
Property Plant and Equipment Gross 976,559



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312008-12-312007-12-31
> Total Assets 
874,106
745,351
882,131
813,954
2,718,750
2,748,754
2,727,202
2,904,305
2,795,028
2,843,882
3,286,149
2,980,099
2,826,103
2,893,703
2,934,750
3,036,851
3,140,921
3,149,173
3,222,089
3,264,069
3,181,706
3,144,526
3,247,807
3,252,053
3,326,321
3,303,473
3,409,447
3,421,137
3,404,000
3,388,269
3,485,747
3,541,030
3,499,059
3,576,323
3,682,038
3,815,616
3,831,785
3,868,281
3,917,202
5,566,395
5,639,607
5,620,067
5,272,703
5,283,753
5,238,315
5,198,241
5,022,183
5,060,932
5,091,658
5,080,568
5,190,932
5,277,938
5,354,608
5,412,250
5,291,040
5,359,706
5,291,698
5,561,717
5,780,604
5,780,6045,561,7175,291,6985,359,7065,291,0405,412,2505,354,6085,277,9385,190,9325,080,5685,091,6585,060,9325,022,1835,198,2415,238,3155,283,7535,272,7035,620,0675,639,6075,566,3953,917,2023,868,2813,831,7853,815,6163,682,0383,576,3233,499,0593,541,0303,485,7473,388,2693,404,0003,421,1373,409,4473,303,4733,326,3213,252,0533,247,8073,144,5263,181,7063,264,0693,222,0893,149,1733,140,9213,036,8512,934,7502,893,7032,826,1032,980,0993,286,1492,843,8822,795,0282,904,3052,727,2022,748,7542,718,750813,954882,131745,351874,106
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,239,291
2,266,400
2,302,028
2,360,041
2,431,726
2,393,558
2,389,161
2,403,583
2,355,984
2,311,684
2,244,370
2,274,325
2,297,605
2,276,529
2,356,429
2,402,823
2,402,823
2,239,745
2,625,403
2,636,641
2,722,143
3,015,511
2,818,535
2,818,5353,015,5112,722,1432,636,6412,625,4032,239,7452,402,8232,402,8232,356,4292,276,5292,297,6052,274,3252,244,3702,311,6842,355,9842,403,5832,389,1612,393,5582,431,7262,360,0412,302,0282,266,4002,239,291000000000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
764,293
801,750
1,548,003
1,589,744
1,579,124
1,643,540
1,691,951
1,757,682
1,674,168
1,617,124
1,561,338
1,560,804
1,481,456
1,525,046
1,651,905
1,666,851
1,643,509
1,473,333
1,793,292
1,960,281
1,885,047
2,124,873
1,988,965
1,988,9652,124,8731,885,0471,960,2811,793,2921,473,3331,643,5091,666,8511,651,9051,525,0461,481,4561,560,8041,561,3381,617,1241,674,1681,757,6821,691,9511,643,5401,579,1241,589,7441,548,003801,750764,293000000000000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
700,000
0
0
0
0
0
0
0
0
0
0
0
70,701
70,701
0
0
0
0
200,320
0
0
0
160,544
160,544000200,320000070,70170,70100000000000700,000000000000000000000000000000000000000
       Net Receivables 
79,499
33,315
30,081
87,185
127,116
152,059
64,546
139,899
221,896
229,333
251,070
333,545
403,820
337,454
349,006
370,315
470,516
432,708
309,628
407,229
403,948
326,673
256,230
309,191
338,179
310,793
213,731
292,119
364,490
293,970
264,007
366,052
359,941
317,145
289,493
398,029
458,355
448,970
446,125
173,400
172,484
177,516
392,773
373,651
406,673
472,663
397,443
443,407
453,908
423,504
421,432
472,075
472,075
501,228
118,041
409,860
455,383
521,743
44,728
44,728521,743455,383409,860118,041501,228472,075472,075421,432423,504453,908443,407397,443472,663406,673373,651392,773177,516172,484173,400446,125448,970458,355398,029289,493317,145359,941366,052264,007293,970364,490292,119213,731310,793338,179309,191256,230326,673403,948407,229309,628432,708470,516370,315349,006337,454403,820333,545251,070229,333221,896139,89964,546152,059127,11687,18530,08133,31579,499
       Other Current Assets 
2,106
172
12,611
6,250
15,746
40,745
55,782
55,508
99,887
117,568
46,485
155,233
125,852
112,247
11,268
4,491
1,567
1,569
11,336
16,235
16,386
62,090
36,881
1,934
37,102
32,800
45,103
20,733
30,648
28,619
33,513
36,996
37,198
40,248
37,829
715,667
20,211
723,833
25,407
1
28,991
32,886
25,986
18,099
19,883
10,608
47,409
33,752
35,829
28,357
54,317
45,922
45,922
37,943
4,926
23,406
178,488
198,163
75,344
75,344198,163178,48823,4064,92637,94345,92245,92254,31728,35735,82933,75247,40910,60819,88318,09925,98632,88628,991125,407723,83320,211715,66737,82940,24837,19836,99633,51328,61930,64820,73345,10332,80037,1021,93436,88162,09016,38616,23511,3361,5691,5674,49111,268112,247125,852155,23346,485117,56899,88755,50855,78240,74515,7466,25012,6111722,106
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,206,354
3,207,880
3,226,509
2,883,542
2,880,170
2,882,331
2,886,557
2,777,813
2,786,608
2,794,052
2,804,039
2,834,503
2,825,405
2,951,785
3,172,505
2,665,636
2,723,065
2,569,554
2,546,207
2,962,069
2,962,0692,546,2072,569,5542,723,0652,665,6363,172,5052,951,7852,825,4052,834,5032,804,0392,794,0522,786,6082,777,8132,886,5572,882,3312,880,1702,883,5423,226,5093,207,8803,206,354000000000000000000000000000000000000000
       Property Plant Equipment 
160,410
163,374
267,665
177,727
276,156
177,788
295,024
213,635
335,684
253,612
477,744
302,300
558,350
521,435
683,972
634,232
769,281
753,933
1,016,944
973,380
1,039,639
1,104,568
1,265,379
1,298,812
1,331,975
1,371,066
1,554,841
1,594,513
1,626,883
1,618,587
1,642,850
1,632,737
1,623,977
1,614,880
1,131,248
1,125,977
1,117,376
1,110,740
1,124,441
1,126,885
1,127,490
1,114,173
1,114,183
1,114,171
1,108,122
1,122,618
1,087,615
1,107,470
1,120,990
1,131,062
1,136,644
1,159,484
1,159,484
1,147,753
1,029,753
1,015,261
1,024,323
1,007,230
976,559
976,5591,007,2301,024,3231,015,2611,029,7531,147,7531,159,4841,159,4841,136,6441,131,0621,120,9901,107,4701,087,6151,122,6181,108,1221,114,1711,114,1831,114,1731,127,4901,126,8851,124,4411,110,7401,117,3761,125,9771,131,2481,614,8801,623,9771,632,7371,642,8501,618,5871,626,8831,594,5131,554,8411,371,0661,331,9751,298,8121,265,3791,104,5681,039,639973,3801,016,944753,933769,281634,232683,972521,435558,350302,300477,744253,612335,684213,635295,024177,788276,156177,727267,665163,374160,410
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
303,351
306,113
294,113
1,894,174
1,894,016
1,895,272
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000001,895,2721,894,0161,894,174294,113306,113303,351000000000000000000000000000000000000
       Intangible Assets 
62,856
106,391
3,837
101,797
3,723
100,736
3,609
100,210
3,480
98,836
3,371
114,785
5,570
115,621
5,042
113,928
4,588
112,406
4,387
99,238
98,421
97,771
97,328
96,631
95,890
95,400
94,469
93,830
93,582
92,888
92,991
92,227
91,696
91,042
142,802
141,818
142,483
141,165
156,388
169,484
18,068
167,501
159,773
158,694
156,298
154,580
148,076
146,937
145,967
145,047
144,223
143,100
142,219
141,154
135,488
134,226
133,314
125,429
124,858
124,858125,429133,314134,226135,488141,154142,219143,100144,223145,047145,967146,937148,076154,580156,298158,694159,773167,50118,068169,484156,388141,165142,483141,818142,80291,04291,69692,22792,99192,88893,58293,83094,46995,40095,89096,63197,32897,77198,42199,2384,387112,4064,588113,9285,042115,6215,570114,7853,37198,8363,480100,2103,609100,7363,723101,7973,837106,39162,856
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,047
11,146
9,242
10,119
10,294
19,113
1,133,516
18,123
1,077
1,563
2,569
5,522
1,757
4,053
105,024
53,722
53,707
53,027
53,506
184,711
184,71153,50653,02753,70753,722105,0244,0531,7575,5222,5691,5631,07718,1231,133,51619,11310,29410,1199,24211,1469,047000000000000000000000000000000000000000
> Total Liabilities 
441,875
270,576
411,260
248,370
155,905
132,123
77,123
93,206
64,182
66,800
135,566
81,993
141,187
134,850
148,133
158,358
158,244
250,531
298,200
274,194
270,987
220,067
337,886
295,223
366,492
331,003
439,502
408,531
436,394
410,214
470,596
484,508
458,973
513,930
602,317
693,261
735,608
734,626
704,846
950,900
1,033,584
967,155
855,855
834,113
762,964
757,386
720,087
723,594
747,461
700,086
780,424
825,555
923,641
940,649
941,661
945,597
902,568
919,456
877,174
877,174919,456902,568945,597941,661940,649923,641825,555780,424700,086747,461723,594720,087757,386762,964834,113855,855967,1551,033,584950,900704,846734,626735,608693,261602,317513,930458,973484,508470,596410,214436,394408,531439,502331,003366,492295,223337,886220,067270,987274,194298,200250,531158,244158,358148,133134,850141,18781,993135,56666,80064,18293,20677,123132,123155,905248,370411,260270,576441,875
   > Total Current Liabilities 
404,005
251,086
407,959
245,070
152,605
128,823
71,023
89,906
58,082
60,700
120,771
75,893
135,087
128,750
133,994
152,258
142,852
143,148
191,016
167,033
163,793
112,966
247,568
205,152
276,239
240,812
369,283
338,572
366,462
340,360
419,068
433,407
407,929
463,000
578,620
670,041
712,455
711,331
684,793
691,836
771,424
704,322
640,330
617,421
548,019
542,591
502,760
500,149
524,390
477,101
552,471
694,661
694,661
712,317
729,984
734,059
691,414
707,507
626,267
626,267707,507691,414734,059729,984712,317694,661694,661552,471477,101524,390500,149502,760542,591548,019617,421640,330704,322771,424691,836684,793711,331712,455670,041578,620463,000407,929433,407419,068340,360366,462338,572369,283240,812276,239205,152247,568112,966163,793167,033191,016143,148142,852152,258133,994128,750135,08775,893120,77160,70058,08289,90671,023128,823152,605245,070407,959251,086404,005
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
15,000
15,000
10,000
20,000
57,777
28,208
26,924
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000026,92428,20857,77720,00010,00015,00015,000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
15,000
15,000
10,000
20,000
57,777
28,208
26,924
20,000
0
0
19,160
18,817
11,363
185
28,140
35,368
43,523
40,409
39,290
59,911
54,862
45,893
28,605
28,60545,89354,86259,91139,29040,40943,52335,36828,14018511,36318,81719,1600020,00026,92428,20857,77720,00010,00015,00015,000000000000000000000000000000000000000
       Accounts payable 
23,718
21,352
7,848
26,520
20,407
19,267
11,317
21,410
18,006
18,302
48,894
24,133
38,786
34,652
57,859
65,511
55,393
42,490
79,746
60,316
62,186
53,121
136,582
68,786
86,659
72,186
229,828
107,073
112,128
76,420
211,976
164,934
155,296
156,141
149,335
113,043
115,126
103,879
34,716
115,421
80,722
71,503
112,799
92,300
100,247
104,668
128,302
120,600
115,856
94,848
90,486
85,444
85,444
90,314
146,379
107,161
81,088
65,686
90,363
90,36365,68681,088107,161146,37990,31485,44485,44490,48694,848115,856120,600128,302104,668100,24792,300112,79971,50380,722115,42134,716103,879115,126113,043149,335156,141155,296164,934211,97676,420112,128107,073229,82872,18686,65968,786136,58253,12162,18660,31679,74642,49055,39365,51157,85934,65238,78624,13348,89418,30218,00621,41011,31719,26720,40726,5207,84821,35223,718
       Other Current Liabilities 
209,127
83,354
220,111
108,550
112,198
89,556
39,706
68,496
40,076
42,398
71,877
51,760
96,301
94,098
76,135
86,747
58,959
72,158
63,270
61,716
56,607
59,845
70,985
106,365
129,580
118,625
89,456
191,500
224,334
233,940
145,663
228,472
214,633
261,859
349,274
501,998
358,596
540,291
296,880
10,000
50
553,465
226,218
471,752
399,164
405,803
207,412
320,426
209,715
344,479
204,480
267,862
267,862
537,754
3,980
510,745
240,792
531,570
1,662
1,662531,570240,792510,7453,980537,754267,862267,862204,480344,479209,715320,426207,412405,803399,164471,752226,218553,4655010,000296,880540,291358,596501,998349,274261,859214,633228,472145,663233,940224,334191,50089,456118,625129,580106,36570,98559,84556,60761,71663,27072,15858,95986,74776,13594,09896,30151,76071,87742,39840,07668,49639,70689,556112,198108,550220,11183,354209,127
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
259,065
262,160
262,833
215,525
216,692
214,945
214,796
217,327
223,445
223,071
222,984
227,953
228,003
228,980
228,332
211,677
211,538
211,154
211,949
250,907
250,907211,949211,154211,538211,677228,332228,980228,003227,953222,984223,071223,445217,327214,796214,945216,692215,525262,833262,160259,065000000000000000000000000000000000000000
       Other Liabilities 
0
0
3,301
3,300
3,300
3,300
6,100
3,300
6,100
6,100
14,795
6,100
6,100
6,100
14,139
6,100
15,392
17,383
17,184
17,162
17,194
17,100
20,319
20,071
20,253
20,192
20,219
19,959
19,932
19,855
21,529
21,101
21,044
20,931
13,697
13,220
13,153
13,295
20,053
259,065
262,160
262,833
215,525
216,692
214,945
214,796
217,327
217,109
216,654
216,487
221,754
222,640
222,640
222,543
0
206,169
206,215
207,010
0
0207,010206,215206,1690222,543222,640222,640221,754216,487216,654217,109217,327214,796214,945216,692215,525262,833262,160259,06520,05313,29513,15313,22013,69720,93121,04421,10121,52919,85519,93219,95920,21920,19220,25320,07120,31917,10017,19417,16217,18417,38315,3926,10014,1396,1006,1006,10014,7956,1006,1003,3006,1003,3003,3003,3003,30100
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13,800
13,800
13,800
13,800
13,800
13,800
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000013,80013,80013,80013,80013,80013,800000000000000000000000000000000000000
> Total Stockholder Equity
401,392
432,486
416,840
503,383
2,548,615
2,598,629
2,627,461
2,797,653
2,702,915
2,749,395
3,140,343
2,888,161
2,675,154
2,744,306
2,771,740
2,878,441
2,982,624
2,898,589
2,923,835
2,989,820
2,910,664
2,924,402
2,909,863
2,956,773
2,959,771
2,972,406
2,969,945
3,012,605
2,967,606
2,978,055
3,015,150
3,056,523
3,040,086
3,062,393
3,079,721
3,122,355
3,096,178
3,133,655
3,212,355
4,615,494
4,606,022
4,652,912
4,416,848
4,449,640
4,475,351
4,440,854
4,302,096
4,337,338
4,344,197
4,380,482
4,410,509
4,452,383
4,430,967
4,471,601
4,349,379
4,414,108
4,389,129
4,642,262
4,903,430
4,903,4304,642,2624,389,1294,414,1084,349,3794,471,6014,430,9674,452,3834,410,5094,380,4824,344,1974,337,3384,302,0964,440,8544,475,3514,449,6404,416,8484,652,9124,606,0224,615,4943,212,3553,133,6553,096,1783,122,3553,079,7213,062,3933,040,0863,056,5233,015,1502,978,0552,967,6063,012,6052,969,9452,972,4062,959,7712,956,7732,909,8632,924,4022,910,6642,989,8202,923,8352,898,5892,982,6242,878,4412,771,7402,744,3062,675,1542,888,1613,140,3432,749,3952,702,9152,797,6532,627,4612,598,6292,548,615503,383416,840432,486401,392
   Common Stock
136,455
136,455
136,455
136,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
182,455
0
183,993
183,993
183,993
0
0183,993183,993183,9930182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455182,455136,455136,455136,455136,455
   Retained Earnings 
92,979
94,609
42,083
124,399
174,326
224,340
225,072
391,856
300,613
347,093
496,846
453,341
374,334
443,485
605,033
711,734
814,543
730,588
728,524
1,115,801
1,036,645
1,045,315
1,028,158
1,077,685
1,077,192
1,089,826
1,085,811
1,130,906
1,082,111
1,092,560
1,128,436
1,169,808
1,153,371
1,175,679
1,190,516
1,233,150
1,204,578
1,240,737
1,320,757
990,725
980,418
1,026,327
1,454,233
1,485,920
1,510,800
1,478,666
1,408,112
1,444,166
1,451,119
1,487,583
1,511,972
1,529,189
1,529,189
1,569,859
1,126,560
1,614,738
1,585,826
1,838,310
1,393,729
1,393,7291,838,3101,585,8261,614,7381,126,5601,569,8591,529,1891,529,1891,511,9721,487,5831,451,1191,444,1661,408,1121,478,6661,510,8001,485,9201,454,2331,026,327980,418990,7251,320,7571,240,7371,204,5781,233,1501,190,5161,175,6791,153,3711,169,8081,128,4361,092,5601,082,1111,130,9061,085,8111,089,8261,077,1921,077,6851,028,1581,045,3151,036,6451,115,801728,524730,588814,543711,734605,033443,485374,334453,341496,846347,093300,613391,856225,072224,340174,326124,39942,08394,60992,979
   Capital Surplus 00000000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17,581
18,899
17,579
1,376,693
1,377,527
1,378,509
1,088,596
1,089,701
1,090,532
1,088,170
1,019,965
1,019,153
1,019,059
1,018,880
1,024,518
1,027,759
1,027,759
1,027,723
0
924,876
925,490
926,138
0
0926,138925,490924,87601,027,7231,027,7591,027,7591,024,5181,018,8801,019,0591,019,1531,019,9651,088,1701,090,5321,089,7011,088,5961,378,5091,377,5271,376,69317,57918,89917,581000000000000000000000000000000000000



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue1,153,033
Cost of Revenue-468,152
Gross Profit684,881684,881
 
Operating Income (+$)
Gross Profit684,881
Operating Expense-1,021,081
Operating Income131,952-336,199
 
Operating Expense (+$)
Research Development105,624
Selling General Administrative343,548
Selling And Marketing Expenses-
Operating Expense1,021,081449,172
 
Net Interest Income (+$)
Interest Income60,529
Interest Expense-746
Other Finance Cost-131
Net Interest Income59,653
 
Pretax Income (+$)
Operating Income131,952
Net Interest Income59,653
Other Non-Operating Income Expenses-
Income Before Tax (EBT)420,214131,952
EBIT - interestExpense = -746
361,828
362,574
Interest Expense746
Earnings Before Interest and Taxes (EBIT)-420,960
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax420,214
Tax Provision-58,386
Net Income From Continuing Ops361,828361,828
Net Income361,828
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--59,653
 

Technical Analysis of Tianjin Lisheng Pharmaceutical Co Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Tianjin Lisheng Pharmaceutical Co Ltd. The general trend of Tianjin Lisheng Pharmaceutical Co Ltd is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Tianjin Lisheng Pharmaceutical Co Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Tianjin Lisheng Pharmaceutical Co Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 25.32 < 25.78 < 26.18.

The bearish price targets are: 23.95 > 23.40 > 17.66.

Tweet this
Tianjin Lisheng Pharmaceutical Co Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Tianjin Lisheng Pharmaceutical Co Ltd. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Tianjin Lisheng Pharmaceutical Co Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Tianjin Lisheng Pharmaceutical Co Ltd.

Tianjin Lisheng Pharmaceutical Co Ltd Daily Moving Average Convergence/Divergence (MACD) ChartTianjin Lisheng Pharmaceutical Co Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Tianjin Lisheng Pharmaceutical Co Ltd. The current adx is .

Tianjin Lisheng Pharmaceutical Co Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Tianjin Lisheng Pharmaceutical Co Ltd.

Tianjin Lisheng Pharmaceutical Co Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Tianjin Lisheng Pharmaceutical Co Ltd.

Tianjin Lisheng Pharmaceutical Co Ltd Daily Relative Strength Index (RSI) ChartTianjin Lisheng Pharmaceutical Co Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Tianjin Lisheng Pharmaceutical Co Ltd.

Tianjin Lisheng Pharmaceutical Co Ltd Daily Stochastic Oscillator ChartTianjin Lisheng Pharmaceutical Co Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Tianjin Lisheng Pharmaceutical Co Ltd.

Tianjin Lisheng Pharmaceutical Co Ltd Daily Commodity Channel Index (CCI) ChartTianjin Lisheng Pharmaceutical Co Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Tianjin Lisheng Pharmaceutical Co Ltd.

Tianjin Lisheng Pharmaceutical Co Ltd Daily Chande Momentum Oscillator (CMO) ChartTianjin Lisheng Pharmaceutical Co Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Tianjin Lisheng Pharmaceutical Co Ltd.

Tianjin Lisheng Pharmaceutical Co Ltd Daily Williams %R ChartTianjin Lisheng Pharmaceutical Co Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Tianjin Lisheng Pharmaceutical Co Ltd.

Tianjin Lisheng Pharmaceutical Co Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Tianjin Lisheng Pharmaceutical Co Ltd.

Tianjin Lisheng Pharmaceutical Co Ltd Daily Average True Range (ATR) ChartTianjin Lisheng Pharmaceutical Co Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Tianjin Lisheng Pharmaceutical Co Ltd.

Tianjin Lisheng Pharmaceutical Co Ltd Daily On-Balance Volume (OBV) ChartTianjin Lisheng Pharmaceutical Co Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Tianjin Lisheng Pharmaceutical Co Ltd.

Tianjin Lisheng Pharmaceutical Co Ltd Daily Money Flow Index (MFI) ChartTianjin Lisheng Pharmaceutical Co Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Tianjin Lisheng Pharmaceutical Co Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-13CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-18BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-25STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-22ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-30WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-31SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-08RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-26WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-19MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-25MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

Tianjin Lisheng Pharmaceutical Co Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Tianjin Lisheng Pharmaceutical Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose24.700
Total0/1 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Tianjin Lisheng Pharmaceutical Co Ltd with someone you think should read this too:
  • Are you bullish or bearish on Tianjin Lisheng Pharmaceutical Co Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Tianjin Lisheng Pharmaceutical Co Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Tianjin Lisheng Pharmaceutical Co Ltd

I send you an email if I find something interesting about Tianjin Lisheng Pharmaceutical Co Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Tianjin Lisheng Pharmaceutical Co Ltd.

Receive notifications about Tianjin Lisheng Pharmaceutical Co Ltd in your mailbox!